Walter Kim
Medical Oncology · Scottsdale, AZNPI 1568451649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,426 of the $5,532 with a category attached, or 80.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,218 and has fallen 60.8% since, to $869 in 2025. That places this record below the midpoint for medical oncology clinicians in AZ, where the typical reported total is $8,518.
Across 154 payments — averaging $35.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$773
- Bayer$557
- Puma Biotechnology, Inc.$466
- Stemline Therapeutics Inc.$415
- Seagen Inc.$307
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,42680%
- Education$2244%
- Other$88216%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $1,002 |
| Pfizer | 21 | $773 |
| Bayer | 20 | $557 |
| Puma Biotechnology, Inc. | 16 | $466 |
| Stemline Therapeutics Inc. | 9 | $415 |
| Seagen Inc. | 9 | $307 |
| Eisai Inc. | 8 | $267 |
| Tempus AI, Inc | 4 | $200 |
| Lilly USA, LLC | 5 | $188 |
| EMD Serono, Inc. | 4 | $173 |
| Beone Medicines USA, Inc. | 2 | $161 |
| Mirati Therapeutics, Inc. | 3 | $150 |
| Progenics Pharmaceuticals, Inc. | 2 | $150 |
| Johnson & Johnson | 7 | $115 |
| Merck | 4 | $104 |
| Array Biopharma Inc | 5 | $98 |
| Taiho Oncology, Inc. | 4 | $86 |
| AstraZeneca | 5 | $85 |
| AVEO Pharmaceuticals, Inc. | 2 | $44 |
| Gilead | 1 | $40 |
| Medline Industries LP | 1 | $37 |
| Incyte Corporation | 1 | $27 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Foundation Medicine, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,532 in reported general payments places this provider in the 40th percentile of 59 medical oncology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $6,465 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $5,635 |
| VascepaIcosapent Ethyl | 20 | $4,967 |
| Celecoxib | 68 | $2,776 |
| Glipizide-MetforminGlipizide/Metformin Hcl | 11 | $640 |
| Memantine Hcl ErMemantine Hcl | 11 | $528 |
| Anastrozole | 42 | $502 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $260 |
| Bicalutamide | 12 | $225 |
| Tamsulosin Hcl | 13 | $129 |
| Hydralazine Hcl | 11 | $119 |
| Prednisone | 31 | $118 |
| Atorvastatin Calcium | 26 | $114 |
| Ezetimibe | 13 | $84 |
| Oxycodone Hcl | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $115 | $6,46511 claims |
| MerckJanumet | $104 | $5,63511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Scottsdale
- Daniel von HoffScottsdale$165K
- Erkut BorazanciScottsdale$31K
- Rajinder GroverScottsdale$13K
- Rishi AgarwalScottsdale$12K
- Ashish ChintakuntlawarScottsdale$2K
- John BibbScottsdale$713
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.